Eprosartan in the primary prevention of cardiac allograft vascular disease: A double-blind prospectively randomized study using intravascular ultrasound

Journal of International Medical Research

Volumn 36, Issue 5, 2008, Pages 1022-1031

  Pethig, K ^a   Hornig, B ^b   Bara, C ^b   Schieffer, B ^c   Haverich, A ^b   Sachse, Alisia ^d  

^a EVANGELISCHES KRANKENHAUS   (Germany)

^b Department of Cardiology ^*

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Angiotensin receptor blockers; Antihypertensive agents; Cardiac allograft vasculopathy; Diltiazem; End stage heart failure; Eprosartan; Heart transplantation; Prevention

Indexed keywords

DILTIAZEM; EPROSARTAN; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY FLOW RESERVE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; VIRUS INFECTION; ALLOTRANSPLANTATION; ENDOSCOPIC ECHOGRAPHY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULAR DISEASE;

ACRYLATES; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HEART TRANSPLANTATION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIOPHENES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR DISEASES;

EID: 54449096903     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600520     Document Type: Article

References (27)

1. Hosenpud J, Bennett L, Keck B, et al: The Registry of the International Society of Heart and Lung Transplantation: sixteenth official report-1999. J Heart Lung Transplant 1999; 18: 611-626.
2. O'Connell J, Bourge R, Costanzo-Nordin M, et al: Cardiac transplantation: recipient selection, donor procurement, and medical follow up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992; 86: 1061-1079.
3. Costanzo-Nordin M: Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11: S90-S103.
4. Drinkwator D, Rudis E, Laks H, et al: University of Wisconsin solution versus Stanford cardioplegic solution and the development of cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: 891-896.
5. Escobar A, Ventura H, Stapleton D, et al: Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74: 1042-1046.
6. Johnson M: Transplant coronary disease; nonimmunalogic risk factors. J Heart Lung Transplant 1992; 11; S124-S132.
7. Kobashigawa J, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
8. Koskinen P, Nieminen M, Krogerus L, et al: Cytomegalovirus infection and accelerated cardiac allograft vasculapathy in human cardiac allografts. J Heart Lung Transplant 1993; 12: 724-729.
9. Pethig K, Hoffmann A, Heublein B, et al: Angiotensin-converting enzyme polymorphism. and allograft vasculopathy after heart transplantation: impact of genotype on onset and progression: of disease. Eur Heart J 1998; 19: S254 [abstract].
10. Slataper R, Vicknair N, Sadler R, et al: Comparative effects of different of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973-980.
11. Hadeishi H, Mayberg MR, Seto M: Local application of calcium antagonists inhibits intimal hyperplasia after arterial injury. Neurosurgery 1994; 34: 114-121.
12. Pethig K, Heublein B, Meliss R, et al: Volumetric remodelling of the proximal left coronary artery: early versus late after heart transplantation. J Am Coll Cardiol 1999; 34: 197-203.
13. Yousufuddin M, Haji S, Starling R, et al: Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J 2004; 25: 377-385.
14. Schroeder JS, Gao SZ, Alderman EL, et al: A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164-170.
15. Li H, Tanaka K, Oeser B, et al: Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study. Eur Heart J 2006; 27: 1671-1677.
16. Brozena S, Johnson M, Ventura H, et al: Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trial. J Am Coll Cardiol 1996; 27: 1707-1712.
17. Cai W, Ruan LW, Wang YN, et al: Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis. J Zhejiang Univ Sci B 2006; 7: 648-653.
18. Rakugi H, Jacob HJ, Krieger JE, et al: Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993; 87: 283-290.
19. Sleight P: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18-20.
20. Klahr S, Morrissey J: Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31: 171-176.
21. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
22. Furukawa Y, Matsumori A, Hirozane T, et al: Angiotensin II receptor antagonist TCV-116 reduces graft coronary disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 1996; 93: 333-339.
23. Wenke K, Meiser B, Thiery J, et al: Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398-1402.
24. Cid MC: Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve Clin J Med 2002; 69(suppl 2): SII45 - SII49.
25. Weis M, Phlivanli S, Von Scheidt W: Heart allograft endothelial cell dysfunction. Cause, course and consequences. Z Kardiol 2000; 89(suppl): 58-62.
26. Meldrum DR, Ayala A, Chaudry IH: Mechanism of diltiazem's immunomodulatory effects after hemorrhage and resuscitation. Am J Physiol 1993; 265: 412-421.
27. Di Filippo S: Cochat P, Bozio A: The challenge of renal function in heart transplant children. Pediatr Nephrol 2007; 22: 333-342.